{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:12:16Z","timestamp":1769551936310,"version":"3.49.0"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The standard treatment of unresectable biliary tract cancer (BTC) has shown an insufficient response rate (RR). Our retrospective setting revealed that a combination therapy consisting of intra-arterial chemotherapy plus radiation therapy (IAC + RT) provided a high RR and long-term survival benefits in unresectable BTC. This prospective study aimed to test the effectiveness and safety of IAC + RT as the first-line therapy. The regimen included one-shot IAC with cisplatin, 3\u20136 months of reservoir IAC (5-FU and cisplatin, q\/week), and 50.4 Gy of external radiation. The primary endpoints include the RR, disease control rate, and adverse event rate. This study included seven patients with unresectable BTC without distant metastasis, with five cases classified as stage 4. RT was completed in all cases, and the median number of reservoir IAC sessions was 16. The RR was 57.1% for imaging and 71.4% for clinical assessment, and the disease control rate was 100%, indicating a high antitumor efficacy, which allowed two cases to be transferred to surgery. Five cases of leukopenia and neutropenia; four cases of thrombocytopenia; and two cases of hemoglobin depletion, pancreatic enzyme elevation, and cholangitis were observed, but with no treatment-related deaths. This study revealed a very high antitumor effect with IAC + RT for some unresectable BTC, and it could be useful for conversion therapy.<\/jats:p>","DOI":"10.3390\/cancers15092616","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T02:08:42Z","timestamp":1683252522000},"page":"2616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effectiveness of the Combination of Arterial Infusion Chemotherapy and Radiotherapy for Biliary Tract Cancer: A Prospective Pilot Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-3038","authenticated-orcid":false,"given":"Takuma","family":"Goto","sequence":"first","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-1840","authenticated-orcid":false,"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shugo","family":"Fujibayashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemasa","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-4000","authenticated-orcid":false,"given":"Sayaka","family":"Yuzawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Asahikawa Medical University Hospital, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-3341","authenticated-orcid":false,"given":"Syunta","family":"Ishitoya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Yamashina","sequence":"additional","affiliation":[{"name":"Department of Radiology, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: An updated comprehensive review","volume":"27","author":"Elveni","year":"2022","journal-title":"Ann Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdn533","article-title":"Epidemiology of biliary tract cancers: An update","volume":"20","author":"Randi","year":"2009","journal-title":"Ann Oncol."},{"key":"ref_4","unstructured":"Cancer Statistics (2023, March 20). Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare). Available online: https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jhbp.314","article-title":"Biliary tract cancer registry in Japan from 2008 to 2013","volume":"23","author":"Ishihara","year":"2016","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update","volume":"61","author":"Khan","year":"2012","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jso.24093","article-title":"Multimodality treatment of intrahepatic cholangiocarcinoma: A review","volume":"113","author":"Simo","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","article-title":"Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan","volume":"16","author":"Miyakawa","year":"2009","journal-title":"J. Hepatobiliary Pancreat. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with Cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00280-010-1443-5","article-title":"A multi-institution phase II study of gemcitabine\/S-1 combination chemotherapy for patients with advanced biliary tract cancer","volume":"67","author":"Kanai","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/cas.12218","article-title":"Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)","volume":"104","author":"Morizane","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_13","first-page":"3009","article-title":"Capecitabine plus hepatic intra- arterial epirubicin and cisplatin in unresectable biliary cancer: A phase II study","volume":"27","author":"Mambrini","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","article-title":"Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: AMulti-institutional Analysis intra-arterial therapy (IAT) for, I.C.C","volume":"20","author":"Hyder","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2147\/OTT.S166246","article-title":"Intra-arterial chemotherapy improved survival of stage 2\u20133 gallbladder cancer after curative resection","volume":"11","author":"Chen","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00432-010-0783-1","article-title":"Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases","volume":"136","author":"Jiang","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Moureau-Zabotto, L., Turrini, O., Resbeut, M., Raoul, J.L., Giovannini, M., Poizat, F., Piana, G., Delpero, J.R., and Bertucci, F. (2013). Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-568"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijrobp.2008.03.018","article-title":"Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma","volume":"72","author":"Shinohara","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"597813","DOI":"10.3389\/fonc.2020.597813","article-title":"High response rate and prolonged survival of unresectable biliary tract cancer treated with a new combination therapy consisting of intraarterial chemotherapy plus radiotherapy","volume":"10","author":"Goto","year":"2020","journal-title":"Front Oncol."},{"key":"ref_20","first-page":"1755","article-title":"Pharmacokinetics in Arterial Infusion Chemotherapy","volume":"20","author":"Arai","year":"1993","journal-title":"Gan Kagaku Ryoho."},{"key":"ref_21","first-page":"841","article-title":"Current status of biliary and pancreatic cancer chemotherapy in Japan","volume":"21","author":"Fukuda","year":"2000","journal-title":"Tan Sui."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Graham, J.S., Boyd, K., Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Harden, S., and B\u00fctzberger-Zimmerli, P. (2016). A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Res. Notes, 9.","DOI":"10.1186\/s13104-015-1778-4"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"JCO"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejso.2011.03.135","article-title":"Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group","volume":"37","author":"Regimbeau","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1477-2574.2011.00431.x","article-title":"Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: An exploratory analysis of the BT22 study","volume":"14","author":"Fukutomi","year":"2012","journal-title":"HPB"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/9\/2616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:29:27Z","timestamp":1760124567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/9\/2616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15092616"],"URL":"https:\/\/doi.org\/10.3390\/cancers15092616","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}